J 2021

Renin-angiotensin system inhibitors and mortality among diabetic patients with STEMI undergoing mechanical reperfusion during the COVID-19 pandemic

GIUSEPPE, De Luca, Matteo NARDIN, Magdy ALGOWHARY, Berat UGUZ, Dinaldo C OLIVEIRA et. al.

Základní údaje

Originální název

Renin-angiotensin system inhibitors and mortality among diabetic patients with STEMI undergoing mechanical reperfusion during the COVID-19 pandemic

Autoři

GIUSEPPE, De Luca, Matteo NARDIN, Magdy ALGOWHARY, Berat UGUZ, Dinaldo C OLIVEIRA, Vladimir GANYUKOV, Zan ZIMBAKOV, Miha CERCEK, Lisette Okkels JENSEN, Poay Huan LOH, Lucian CALMAC, Gerard Roura FERRER, Alexandre QUADROS, Marek MILEWSKI, di Uccio Fortunato SCOTTO, von Birgelen CLEMENS, Francesco VERSACI, Ten Berg JURRIEN, Gianni CASELLA, Aaron Wong Sung LUNG, Petr KALA (203 Česká republika, domácí), Jose Luis Diez GIL, Xavier CARRILLO, Maurits DIRKSEN, Victor M BECERRA-MUNOZ, Michael Kang-yin LEE, Dafsah Arifa JUZAR, Rodrigo de Moura JOAQUIM, Roberto PALADINO, Davor MILICIC, Periklis DAVLOUROS, Nikola BAKRACESKI, Filippo ZILIO, Luca DONAZZAN, Adriaan KRAAIJEVELD, Gennaro GALASSO, Arpad LUX, Lucia MARINUCCI, Vincenzo GUIDUCCI, Maurizio MENICHELLI, Alessandra SCOCCIA, Aylin Hatice YAMAC, Kadir Ugur MERT, Xacobe Flores RIOS, Tomas KOVARNIK, Michal KIDAWA, Jose MOREU, Vincent FLAVIEN, Enrico FABRIS, Inigo Lozano MARTINEZ-LUENGAS, Marco BOCCALATTE, Francisco Bosa OJEDA, Carlos ARELLANO-SERRANO, Gianluca CAIAZZO, Giuseppe CIRRINCIONE, Hsien-Li KAO, Juan Sanchis FORES, Luigi VIGNALI, Helder PEREIRA, Stephane MANZO, Santiago ORDONEZ, Alev Arat OZKAN, Bruno SCHELLER, Heidi LEHTOLA, Rui TELES, Christos MANTIS, Ylitalo ANTTI, Joao Antonio Brum SILVEIRA, Rodrigo ZONI, Ivan BESSONOV, Stefano SAVONITTO, George KOCHIADAKIS, Dimitrios ALEXOPULOS, Carlos E URIBE, John KANAKAKI, Benjamin FAURIE, Gabriele GABRIELLI, Alejandro Gutierrez BARRIOS, Juan Pablo BACHINI, Alex ROCHA, Frankie Chor-Cheung TAM, Alfredo RODRIGUEZ, Antonia Anna LUKITO, Veauthyelau SAINT-JOY, Gustavo PESSAH, Andrea TUCCILLO, Giuliana CORTESE, Guido PARODI, Mohammed Abed BOURAGHDA, Elvin KEDHI, Pablo LAMELAS, Harry SURYAPRANATA a Monica VERDOIA

Vydání

DIABETES EPIDEMIOLOGY AND MANAGEMENT, AMSTERDAM, ELSEVIER, 2021, 2666-9706

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30202 Endocrinology and metabolism

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.deman.2021.100022

UT WoS

001138302700007

Klíčová slova anglicky

renin-angiotensin system inhibitors; diabetic patients; COVID-19

Štítky

14110211, rivok

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 11. 7. 2024 08:06, Mgr. Tereza Miškechová

Anotace

V originále

Background: During the coronavirus disease 2019 (COVID-19) pandemic, concerns have been arisen on the use of renin-angiotensin system inhibitors (RASI) due to the potentially increased expression of Angiotensin-converting-enzyme (ACE)2 and patient's susceptibility to SARS-CoV2 infection. Diabetes mellitus have been recognized favoring the coronavirus infection with consequent increase mortality in COVID-19. No data have been so far reported in diabetic patients suffering from ST-elevation myocardial infarction (STEMI), a very high-risk population deserving of RASI treatment.Methods: The ISACS-STEMI COVID-19 registry retrospectively assessed STEMI patients treated with primary percutaneous coronary intervention (PPCI) in March/June 2019 and 2020 in 109 European high-volume pri-mary PCI centers. This subanalysis assessed the prognostic impact of chronic RASI therapy at admission on mortality and SARS-CoV2 infection among diabetic patients.Results: Our population is represented by 3812 diabetic STEMI patients undergoing mechanical reperfusion, 2038 in 2019 and 1774 in 2020. Among 3761 patients with available data on chronic RASI therapy, between those ones with and without treatment there were several differences in baseline characteristics, (similar in both periods) but no difference in the prevalence of SARS-CoV2 infection (1.6% vs 1.3%, respectively, p = 0.786). Considering in-hospital medication, RASI therapy was overall associated with a significantly lower in-hospital mortality (3.3% vs 15.8%, p < 0.0001), consistently both in 2019 and in 2010.Conclusions: This is first study to investigate the impact of RASI therapy on prognosis and SARS-CoV2 infec-tion of diabetic patients experiencing STEMI and undergoing PPCI during the COVID-19 pandemic. Both pre-admission chronic RASI therapy and in-hospital RASI did not negatively affected patients' survival during the hospitalization, neither increased the risk of SARS-CoV2 infection. Trial registration number: NCT 04412655 (c) 2021 Published by Elsevier Masson SAS.
Zobrazeno: 3. 11. 2024 12:56